Importance
The association of biomarkers with patient survival after recurrence (SAR) is poorly understood, yet may guide management and treatment.
Objective
To determine the association of DNA mismatch repair (MMR) status and somatic mutations in BRAFV600E or KRAS (exon 2) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant FOLFOX-based chemotherapy.
Design
Tumor biomarkers were analyzed in relationship to SAR in participants in adjuvant chemotherapy trials.
Intervention
Patients with resected, stage III colon cancers who were randomized to adjuvant FOLFOX ± cetuximab (NCCTG N0147) or FOLFOX ± bevacizumab (NSABP C-08).
Main Outcome Measure(s)
Associations of biomarkers with SAR were analyzed using Cox proportional hazards models adjusted for clinicopathological features and time-to-recurrence. The interaction effect of primary tumor sidedness on the association of biomarkers with SAR was determined.
Results
Among patients with cancer recurrence [N0147 (N=871); C-08 (N= 524)], multivariable analysis revealed that those whose tumors had deficient (d) vs proficient (p) MMR had significantly better SAR (adjusted hazard ratio [HRadj.], 0.70, 95% CI, 0.52 - 0.96, adjusted P [Padj.] <.029). Patients whose tumors harbored mutant BRAFV600E (HRadj., 2.45, 95% CI, 1.85 - 3.25, Padj.<.0001) or mutant KRAS (HRadj., 1.21, 95% CI, 1.00 - 1.47, Padj.=0.052) had worse SAR compared to tumors that had wild-type copies of both genes, although only results for BRAFV600E achieved statistical significance. Significant interactions were found for MMR (Padj.=.029) and KRAS (Padj.=.025) by primary tumor site for SAR. Improved SAR was observed for patients with dMMR tumors of the proximal vs distal colon (HRadj., 0.57, 95% CI, 0.40 - 0.83, Padj. =.003), and worse SAR for mutant KRAS tumors of the distal colon (codon 12: HRadj., 1.76, 95% CI, 1.30 - 2.38, Padj. =.0003; codon 13: HRadj., 1.76, 95% CI, 1.08 - 2.86, Padj. =.022].
Conclusions and Relevance
In patients with recurrence, dMMR was significantly associated with better SAR and this benefit was limited to primary tumors of the proximal colon. Mutations in BRAFV600E were significantly associated with worse SAR, and worse SAR for BRAFV600E or KRAS mutant tumors was more strongly associated with distal cancers. These biomarkers have implications for patient management at recurrence.
Trial Registration
NCCTG NO147, NCT00079274; NSABP C-08, NCT00096278